Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
Modulation of RNA splicing enhances response to BCL2 inhibition in leukemia.
Journal: Cancer cell
Published: May 02, 2022
Phase 1b/2 study of ibrutinib and lenalidomide with dose-adjusted EPOCH-R in patients with relapsed/refractory diffuse large B-cell lymphoma.
Journal: Leukemia & lymphoma
Published: April 15, 2021
Application of Real-World Data to External Control Groups in Oncology Clinical Trial Drug Development.
Journal: Frontiers in oncology
Published: April 15, 2021
Starting dose selection and dose escalation for oncology small molecule first-in-patient trials: learnings from a survey of FDA-approved drugs.
Journal: Cancer chemotherapy and pharmacology
Published: October 13, 2020
The combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphoma.
Journal: British journal of haematology
Published: September 13, 2019
Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies.
Journal: British journal of haematology
Published: March 16, 2017
Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma.
Journal: Blood
Published: October 21, 2016
The role of PIM1 in the ibrutinib-resistant ABC subtype of diffuse large B-cell lymphoma.
Journal: American journal of cancer research
Published: October 18, 2016
Combination of Ibrutinib and ABT-199 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma.
Journal: Molecular cancer therapeutics
Published: August 23, 2016
Last Updated: 09/26/2026